All In Biotech

Drug Trial Radar · NCT01343004

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture

Last checked: Nov 20, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,463 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,463

Actual

Start

Apr 2011

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Radius Health, Inc.Industry
Sponsor type
Industry
First posted
Apr 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.

Conditions

  • Osteoporosis
  • Postmenopausal Osteoporosis

Interventions

  • PlaceboDrug

    Placebo 0 mcg subcutaneous daily

  • BA058 80 mcgDrug

    BA058 80 mcg subcutaneous daily

  • teriparatideDrug

    teriparatide 20 mcg subcutaneous daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With New Vertebral Fractures at 18 MonthsTime frame: 18 months

Locations

28 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Lakewood, Colorado

  • Site not named

    Miami, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Bethesda, Maryland

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Brasília, Brazil

  • Site not named

    Curitiba, Brazil

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Vitória, Brazil

  • Site not named

    Brno, Czechia

  • Site not named

    Pardubice, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Ballerup Municipality, Denmark

  • Site not named

    Vejle, Denmark

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Bialystok, Poland

  • Site not named

    Katowice, Poland

  • Site not named

    Kielce, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Zgierz, Poland

  • Site not named

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.